Literature DB >> 7273765

Pharmacokinetics of norethisterone oenanthate in humans.

G W Sang, K Fotherby, G Howard, M Elder, P G Bye.   

Abstract

The pharmacokinetics of a dose of 200 mg NET-OEN were studied after intramuscular injection into nine subjects. Blood levels of NET and NET-OEN increased rapidly, reaching peaks in most subjects within seven days. At all times after injection, serum levels of NET exceeded those of NET-OEN. The half-life of absorption varied from 5.4 to 22.3 days and the half-life of elimination varied from 7.5 to 22.5 days; there was a significant correlation (R = 0.78) between these two half-lives. There were significant correlations between the absorption half-lives and the peak values of NET and NET-OEN, the time to reach peak values and the time for which NET was detectable in serum. In all subjects NET was detectable in the circulation for a longer time after injection (mean value 74 days) than NET-OEN (mean value 43 days). The time for which the two steroids were detectable in the circulation showed a significant correlation with the elimination half-lives but there was no correlation with the peak values attained, the time taken to reach peak values and bioavailability. There was a two-fold variation between the subjects in the bioavailability of NET, less than 5% of the bioavailable NET was released after day 60.

Entities:  

Keywords:  Acceptor Characteristics; Age Factors; Body Weight; Clinical Research; Contraception; Contraceptive Agents, Female; Contraceptive Agents, Progestin--analysis; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--analysis; Contraceptive Agents--pharmacodynamics; Contraceptive Methods; Family Planning; Human Volunteers; Injectables; Norethindrone Enanthate--analysis; Norethindrone Enanthate--pharmacodynamics; Norethindrone--analysis; Norethindrone--pharmacodynamics; Research Methodology

Mesh:

Substances:

Year:  1981        PMID: 7273765     DOI: 10.1016/0010-7824(81)90065-2

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Facts about injectable contraceptives: memorandum from a WHO meeting.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

Review 3.  Long acting contraceptives. Present status.

Authors:  G Benagiano; F M Primiero
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

Review 4.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

5.  The contraceptive medroxyprogesterone acetate, unlike norethisterone, directly increases R5 HIV-1 infection in human cervical explant tissue at physiologically relevant concentrations.

Authors:  Roslyn M Ray; Michelle F Maritz; Chanel Avenant; Michele Tomasicchio; Sigcinile Dlamini; Zephne van der Spuy; Janet P Hapgood
Journal:  Sci Rep       Date:  2019-03-13       Impact factor: 4.379

6.  Medroxyprogesterone acetate, unlike norethisterone, increases HIV-1 replication in human peripheral blood mononuclear cells and an indicator cell line, via mechanisms involving the glucocorticoid receptor, increased CD4/CD8 ratios and CCR5 levels.

Authors:  Michelle F Maritz; Roslyn M Ray; Alexis J Bick; Michele Tomasicchio; John G Woodland; Yashini Govender; Chanel Avenant; Janet P Hapgood
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.